Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapiesSumit Kar, Mallika Singh, Ethan Ahler et al.|Cancer Research|2025Cited by 9